SLNO FY 2025 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$190M

Gross Profit

$188M98.6% margin

Operating Income

$15M7.9% margin

Net Income

$21M11.0% margin

EPS (Diluted)

$0.39

Cash Flow

Operating Cash Flow

$47M

Free Cash Flow

$47M

Stock-Based Comp.

$46M

Balance Sheet

Total Assets

$564M

Total Liabilities

$114M

Stockholders' Equity

$450M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$190M	$0	—
Gross Profit	$188M	$0	—
Operating Income	$15M	-$188M	+108.0%
Net Income	$21M	-$176M	+111.9%